Oteseconazole (VT-1161) for the Management of Dermatophyte Toenail Onychomycosis: A Review of Phase II Trial Subgroup Efficacy and Extended Follow-Up Safety
- 1Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, , Toronto, ON M5S 1A8, Canada
- 2Independent Researcher, London, ON N5X 2P1, Canada
Abstract
Oteseconazole, a synthetic tetrazole antifungal, provides pharmacological advantages that suggest it can be a safe and effective treatment for Trichophyton rubrum onychomycosis. A Phase II study of oteseconazole (VT-1161) for onychomycosis demonstrated good efficacy and safety up to Week 60 in the dosing regimens tested: 300 mg for 12 weeks; 300 mg for 24 weeks; 600 mg for 12 weeks and 600 mg for 24 weeks (all given once daily for 2 weeks, then once weekly for remaining weeks). Additional analysis of efficacy was performed using patient factors that can impact onychomycosis. Similar efficacy rates were found across all four regimens tested. Patient factors (<50 years of age, <50% affected nail area) were more strongly associated with improved outcomes than dose escalation of oteseconazole but did not necessarily predict better overall outcomes. No significant safety concerns were found up to Week 60. New extended follow-up data from Week 60 to Week 96 demonstrated long-term plasma retention of oteseconazole with no additional oteseconazole-related adverse events. Accordingly, clinical photographic assessment at Weeks 72 and 96 showed improvement in the target toenail; however, the number of evaluable patients was limited (n = 22), and mycology testing was not performed. The tetrazole structure of oteseconazole significantly reduces the risk of drug–drug interaction compared to traditional azoles (itraconazole, fluconazole). The favorable safety and efficacy profile suggests oteseconazole could be a potential alternative to itraconazole for onychomycosis at any of the tested doses.
Related
- Subgroup Analysis of Pooled Phase 3 Efficacy Data From Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) Including Participants With Uropathogens Not-Susceptible to Nitrofurantoin
- Clinical characteristics, risk stratification, and subgroup-dependent IVIG efficacy in hospitalized children with infectious mononucleosis: a single-center retrospective study.
- Efficacy of whole-body vibration training in the management of patients with COPD: a systematic review and meta-analysis
- Efficacy and safety of gepants in migraine management: a narrative review focusing on atogepant and rimegepant
- Molecular and Conventional Tests in Onychomycosis: A Systematic Review of Paired Diagnostic Discordance and Clinical Interpretation
BibTeX
@article{gupta2026oteseconazole,
title = {{Oteseconazole (VT-1161) for the Management of Dermatophyte Toenail Onychomycosis: A Review of Phase II Trial Subgroup Efficacy and Extended Follow-Up Safety}},
author = {Aditya K. Gupta and Elizabeth A. Cooper},
journal = {Pathogens (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/pathogens15101098},
url = {https://europepmc.org/article/PMC/PMC13708148},
note = {CC BY},
}
RIS
TY - JOUR
TI - Oteseconazole (VT-1161) for the Management of Dermatophyte Toenail Onychomycosis: A Review of Phase II Trial Subgroup Efficacy and Extended Follow-Up Safety
AU - Aditya K. Gupta
AU - Elizabeth A. Cooper
PY - 2026
DA - 2026/10/01
JO - Pathogens (Basel, Switzerland)
DO - 10.3390/pathogens15101098
UR - https://europepmc.org/article/PMC/PMC13708148
AB - Oteseconazole, a synthetic tetrazole antifungal, provides pharmacological advantages that suggest it can be a safe and effective treatment for Trichophyton rubrum onychomycosis. A Phase II study of oteseconazole (VT-1161) for onychomycosis demonstrated good efficacy and safety up to Week 60 in the dosing regimens tested: 300 mg for 12 weeks; 300 mg for 24 weeks; 600 mg for 12 weeks and 600 mg for 24 weeks (all given once daily for 2 weeks, then once weekly for remaining weeks). Additional analysis of efficacy was performed using patient factors that can impact onychomycosis. Similar efficacy rates were found across all four regimens tested. Patient factors (<50 years of age, <50% affected nail area) were more strongly associated with improved outcomes than dose escalation of oteseconazole but did not necessarily predict better overall outcomes. No significant safety concerns were found up to Week 60. New extended follow-up data from Week 60 to Week 96 demonstrated long-term plasma retention of oteseconazole with no additional oteseconazole-related adverse events. Accordingly, clinical photographic assessment at Weeks 72 and 96 showed improvement in the target toenail; however, the number of evaluable patients was limited (n = 22), and mycology testing was not performed. The tetrazole structure of oteseconazole significantly reduces the risk of drug–drug interaction compared to traditional azoles (itraconazole, fluconazole). The favorable safety and efficacy profile suggests oteseconazole could be a potential alternative to itraconazole for onychomycosis at any of the tested doses.
SN - 2076-0817
ER -